

CORRECTION

Open Access



# Correction: Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC

Armando Santoro<sup>1,2\*</sup>, Garrido Pilar<sup>3</sup>, Daniel S.W. Tan<sup>4</sup>, Jon Zugazagoitia<sup>5</sup>, Frances A. Shepherd<sup>6</sup>, Alessandra Bearz<sup>7</sup>, Fabrice Barlesi<sup>8,9,10</sup>, Tae Min Kim<sup>11</sup>, Tobias R. Overbeck<sup>12</sup>, Enriqueta Felip<sup>13</sup>, Can Cai<sup>14</sup>, Simantini Eddy<sup>14</sup>, Tracey McCulloch<sup>15</sup> and Eric S. Schaefer<sup>16</sup>

**Correction:** *BMC Cancer* 24, 1307 (2024)  
<https://doi.org/10.1186/s12885-024-12841-2>

Following publication of the original article [1], the authors identified an error in the author name of Simantini Eddy. Their given name and family name were erroneously transposed.

The incorrect author name is: Eddy Simantini  
The correct author name is: Simantini Eddy  
The author group has been updated above and the original article [1] has been corrected.

Published online: 21 November 2024

The original article can be found online at <https://doi.org/10.1186/s12885-024-12841-2>.

\*Correspondence:

Armando Santoro  
armando.santoro@cancercenter.humanitas.it; armando.santoro@humanitas.it

<sup>1</sup> Department of Biomedical Sciences, Humanitas University, Milan, Italy

<sup>2</sup> Department of Oncology and Hematology, IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Via Manzoni 56, Rozzano, Milan 20089, Italy

<sup>3</sup> Department of Medical Oncology, Hospital Ramón Y Cajal, Madrid, Spain

<sup>4</sup> Department of Medical Oncology, National Cancer Center Singapore, Singapore, Singapore

<sup>5</sup> Department of Medical Oncology, University Hospital, 12 de Octubre, Madrid, Spain

<sup>6</sup> Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada

<sup>7</sup> Department of Medical Oncology, Centro Di Riferimento Oncologico - CRO, Aviano, Italy

<sup>8</sup> Department of Multidisciplinary Oncology and Therapeutic Innovations, Aix Marseille University, CNRS, INSERM, CRCM, APHM, CEPCM, CLIP, Marseille, France

<sup>9</sup> Faculté de Médecine, Université Paris Saclay, Kremlin Bicêtre, France

<sup>10</sup> Medical Oncology Department, Gustave Roussy, Villejuif, France

## Reference

1. Santoro A, Pilar G, Tan DS, et al. Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC. *BMC Cancer*. 2024;24:1307. <https://doi.org/10.1186/s12885-024-12841-2>.

<sup>11</sup> Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea

<sup>12</sup> Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany

<sup>13</sup> Department of Medical Oncology Service, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain

<sup>14</sup> Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

<sup>15</sup> Novartis Pharma AG, Basel, Switzerland

<sup>16</sup> Department of Medical Oncology, Highlands Oncology Group, Fayetteville, AZ, USA



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.